Mylan nets FDA approval to market generic Lipitor

Justine Varieur Cadet | | Health Imaging | Diagnostic Imaging
Mylan's subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received tentative approval from the FDA for its abbreviated New Drug Application (ANDA) for atorvastatin calcium tablets.

The newly approved doses are 10 mg (base), 20 mg (base), 40 mg (base) and 80 mg (base), according to the Pittsburgh-based Mylan.

Atorvastatin calcium is the generic equivalent to Pfizer's Lipitor, indicated for the prevention of cardiovascular disease and hypercholesterolemia.

 

Justine Varieur Cadet

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.